Skip to main content

Table 1 The drugs significantly associated (FDR < 0.1) with the network-signature classification based on CMAP analysis

From: A network model for angiogenesis in ovarian cancer

Drug name CMAP rank CMAP P-value CMAP FDR
Network signature Expression signature Network signature Expression signature Network signature Expression signature
Harmol 1 61 4.6E-04 1.1 × 10−3 0.015 4.9 × 10−3
Harmalol 2 67 4.9E-04 1.8 × 10−3 0.015 7.1 × 10−3
Brinzolamide 3 95 5.6E-04 5.8 × 10−3 0.016 0.020
Edrophonium chloride 4 42 6.0E-04 3.6 × 10−4 0.017 1.8 × 10−3
Trimethadione 5 138 6.8E-04 0.035 0.018 0.101
Canavanine 6 39 7.0E-04 2.7 × 10−4 0.018 1.5 × 10−3
Oxamniquine 7 49 1.3E-03 6.0 × 10−4 0.025 2.8 × 10−3
Metolazone 8 59 1.3E-03 1.0 × 10−3 0.025 4.4 × 10−3
Etofylline 9 112 3.2E-03 0.015 0.048 0.048
Harmine** 10 613 3.6E-03 1.000 0.051 1.000
Tetracycline 11 108 4.0E-03 0.013 0.056 0.041
Sotalol 12 136 5.5E-03 0.033 0.069 0.096
5213008 13 55 6.5E-03 8.1 × 10−4 0.080 3.7 × 10−3
Prestwick-675 14 1 7.3E-03 6.0 × 10−6 0.084 5.2 × 10−5
Pirinixic acid 15 21 8.6E-03 2.4 × 10−5 0.095 1.8 × 10−4
Dicoumarol** 16 184 8.8E-03 0.239 0.097 0.534
Pentoxyverine** 17 784 9.1E-03 1.000 0.098 1.000
Adipiodone** 18 689 0.010 1.000 0.100 1.000
  1. Drugs that are not significantly associated with the expression-signature are bolded and asterisked (**).